Clinical Trials Browser

Phase 1/2 × Pathologic Complete Response × Clear all

NCT06694454 2026-03-18

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT02789254 2023-12-28

FLYSYN-101

Phase 1/2 Completed

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Leukemia, Myeloid, Acute

NCT01656252 2020-11-03

PrE0901

Phase 1/2 Terminated

15 enrolled 5 charts

Classical hematologyOther hematologic neoplasm

Jacobs syndrome, Pathologic Complete Response, Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute